Reference number : 276-2018-2019-Q3-00149, amendment number : , agreement type : C, recipient legal name : Panag Pharma Inc.|Panag Pharma Inc., recipient country : CA, recipient province : NS, recipient city : Halifax|Halifax, recipient postal code : B3N 2T1, program name english : Business Development Program, program name french : Programme de développement des entreprises, program purpose english : nan, program purpose french : nan, agreement title english : 211967, agreement title french : 211967, agreement number : 211967, agreement value : 500000.0, agreement start date : 2018-11-07, agreement end date : 2020-12-31, description english : Develop and commercialize novel cannabinoid formulations for pain and inflammation, description french : Créer et commercialiser formules inédites de cannabinoïdes contre douleur et inflammation, expected results english : nan, expected results french : nan, additional information english : The assistance type is Unconditionally Repayable Contribution., additional information french : Le type d'aide est Contribution à remboursement inconditionnel., owner organization : acoa-apeca, owner organization title : Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique